Abstract
* The list of collaborators is given at the end of the paper.
Objectives: To determine if the interval between the last negative and the first positive HIV test is associated with demographic characteristics of HIV seroconverters.
Methods: A prospective cohort of patients with HIV seroconversion enrolled in the Lyons HIV hospital database was analysed. Comparisons of demographic characteristics were performed after stratification on the duration of the interval between the last HIV negative screening test and the first HIV positive screening test, which ranged from 1 day to 24 months. Linear regression methods were used to identify the covariates associated with a negative HIV antibody test followed by a positive test.
Results: Age (p=0.54), sex (p=0.78), heterosexual route of infection (p=0.78), other route (p=0.40) compared with homosexual route, and estimated year of HIV infection (p value ranged from 0.84 to 0.95) were not associated with a shorter seroconversion interval after multivariate analyses. The presence of an acute HIV illness was the only predictor of a short seroconversion interval (p=0.006) with a reduction of 84 days of the interval when it was reported.
Conclusions: No selection bias for demographic characteristics of HIV seroconverters seems associated with the length of the seroconversion interval, at least for intervals ≤24 months.
Key Words: selection bias; HIV seroconversion; study design; incidence cohort
Full Text
The Full Text of this article is available as a PDF (116.3 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Carré N., Deveau C., Belanger F., Boufassa F., Persoz A., Jadand C., Rouzioux C., Delfraissy J. F., Bucquet D. Effect of age and exposure group on the onset of AIDS in heterosexual and homosexual HIV-infected patients. SEROCO Study Group. AIDS. 1994 Jun;8(6):797–802. doi: 10.1097/00002030-199406000-00012. [DOI] [PubMed] [Google Scholar]
- Dhenain M., Vanhems P., Fabry J., Chidiac C., Peyramond D., Touraine J. L., Trepo C., Gilibert R. P. Antiretroviral treatment among HIV-1 seroconverters from Lyon, France (1985-1998). Lyon CISIH Collaborators. AIDS. 1999 Dec 3;13(17):2484–2486. doi: 10.1097/00002030-199912030-00026. [DOI] [PubMed] [Google Scholar]
- Greenland S. Modeling and variable selection in epidemiologic analysis. Am J Public Health. 1989 Mar;79(3):340–349. doi: 10.2105/ajph.79.3.340. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kaufmann G. R., Cunningham P., Kelleher A. D., Zaunders J., Carr A., Vizzard J., Law M., Cooper D. A. Patterns of viral dynamics during primary human immunodeficiency virus type 1 infection. The Sydney Primary HIV Infection Study Group. J Infect Dis. 1998 Dec;178(6):1812–1815. doi: 10.1086/314480. [DOI] [PubMed] [Google Scholar]
- Lyles R. H., Muñoz A., Yamashita T. E., Bazmi H., Detels R., Rinaldo C. R., Margolick J. B., Phair J. P., Mellors J. W. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. J Infect Dis. 2000 Mar;181(3):872–880. doi: 10.1086/315339. [DOI] [PubMed] [Google Scholar]
- O'Brien T. R., Hoover D. R., Rosenberg P. S., Chen B., Detels R., Kingsley L. A., Phair J., Saah A. J. Evaluation of secular trends in CD4+ lymphocyte loss among human immunodeficiency virus type 1 (HIV-1)-infected men with known dates of seroconversion. Am J Epidemiol. 1995 Sep 15;142(6):636–642. doi: 10.1093/oxfordjournals.aje.a117687. [DOI] [PubMed] [Google Scholar]
- Pezzotti P., Phillips A. N., Dorrucci M., Lepri A. C., Galai N., Vlahov D., Rezza G. Category of exposure to HIV and age in the progression to AIDS: longitudinal study of 1199 people with known dates of seroconversion. HIV Italian Seroconversion Study Group. BMJ. 1996 Sep 7;313(7057):583–586. doi: 10.1136/bmj.313.7057.583. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Phillips A. N., Grabar S., Tassie J. M., Costagliola D., Lundgren J. D., Egger M. Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups. AIDS. 1999 Oct 22;13(15):2075–2082. doi: 10.1097/00002030-199910220-00010. [DOI] [PubMed] [Google Scholar]
- Vanhems P., Lambert J., Cooper D. A., Perrin L., Carr A., Hirschel B., Vizzard J., Kinloch-de Loës S., Allard R. Severity and prognosis of acute human immunodeficiency virus type 1 illness: a dose-response relationship. Clin Infect Dis. 1998 Feb;26(2):323–329. doi: 10.1086/516289. [DOI] [PubMed] [Google Scholar]
- Veugelers P. J., Page K. A., Tindall B., Schechter M. T., Moss A. R., Winkelstein W. W., Jr, Cooper D. A., Craib K. J., Charlebois E., Coutinho R. A. Determinants of HIV disease progression among homosexual men registered in the Tricontinental Seroconverter Study. Am J Epidemiol. 1994 Oct 15;140(8):747–758. doi: 10.1093/oxfordjournals.aje.a117322. [DOI] [PubMed] [Google Scholar]